CAVERJECT IMPULSE Drug Patent Profile
✉ Email this page to a colleague
When do Caverject Impulse patents expire, and when can generic versions of Caverject Impulse launch?
Caverject Impulse is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in CAVERJECT IMPULSE is alprostadil. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alprostadil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Caverject Impulse
A generic version of CAVERJECT IMPULSE was approved as alprostadil by HIKMA on January 20th, 1998.
Summary for CAVERJECT IMPULSE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 104 |
| Patent Applications: | 4,457 |
| Drug Prices: | Drug price information for CAVERJECT IMPULSE |
| What excipients (inactive ingredients) are in CAVERJECT IMPULSE? | CAVERJECT IMPULSE excipients list |
| DailyMed Link: | CAVERJECT IMPULSE at DailyMed |
Pharmacology for CAVERJECT IMPULSE
| Drug Class | Prostaglandin Analog Prostaglandin E1 Agonist |
| Mechanism of Action | Prostaglandin Receptor Agonists |
| Physiological Effect | Genitourinary Arterial Vasodilation Venous Vasodilation |
Anatomical Therapeutic Chemical (ATC) Classes for CAVERJECT IMPULSE
US Patents and Regulatory Information for CAVERJECT IMPULSE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | CAVERJECT IMPULSE | alprostadil | INJECTABLE;INJECTION | 021212-001 | Jun 11, 2002 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | CAVERJECT IMPULSE | alprostadil | INJECTABLE;INJECTION | 021212-002 | Jun 11, 2002 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CAVERJECT IMPULSE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | CAVERJECT IMPULSE | alprostadil | INJECTABLE;INJECTION | 021212-001 | Jun 11, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | CAVERJECT IMPULSE | alprostadil | INJECTABLE;INJECTION | 021212-001 | Jun 11, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | CAVERJECT IMPULSE | alprostadil | INJECTABLE;INJECTION | 021212-002 | Jun 11, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | CAVERJECT IMPULSE | alprostadil | INJECTABLE;INJECTION | 021212-002 | Jun 11, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | CAVERJECT IMPULSE | alprostadil | INJECTABLE;INJECTION | 021212-001 | Jun 11, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | CAVERJECT IMPULSE | alprostadil | INJECTABLE;INJECTION | 021212-002 | Jun 11, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CAVERJECT IMPULSE
See the table below for patents covering CAVERJECT IMPULSE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Sweden | 8801405 | ⤷ Sign Up | |
| South Africa | 8804616 | ⤷ Sign Up | |
| Spain | 2026695 | ⤷ Sign Up | |
| Germany | 69320802 | ⤷ Sign Up | |
| Croatia | P920949 | A DEVICE FOR INJECTION | ⤷ Sign Up |
| Brazil | 8803170 | ⤷ Sign Up | |
| Australia | 4274093 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
